Inhaled-drug therapy will keep a central role in asthma therapy despite the development of new drug entities with oral administration routes. New developments in the inhalation area will further improve the local-to-systemic-effect ratios of inhalation drugs. This will involve the use of slow-release formulations, optimizing the deposition efficiency, and regional deposition of inhalation drugs (peripheral or central deposition) and further developments to improvement patient compliance (e.g., once-daily dosing). With the availability of more and more generic inhalation devices, questions on how to test bioequivalence will remain. Pharmacokinetic and pharmacokinetic/dynamic approaches will play an important role in streamlining such developments.
Was this article helpful?
If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.